|
| | | | | | | | | | |
| Name | Indication | Class | Rights | Approved | IP | | Price | 117 | |
| Januvia (sitagliptin) | Type 2 Diabetes | DPP4 | 1 | 10/16/2006 | 2022 | | Shares | 2537 | Q123 |
| Janumet (Januvia+metformin) | Type 2 Diabetes | DPP4 | 98%, OSIP | 3/30/2007 | Oral | | MC | 296829 | |
| Keytruda (pembrolizumab) | Melanoma, NSCLC | PD-1 | 1 | 9/4/2014 | IV | | Cash | 11677 | Q123 |
| Remicade (infliximab) | Rheumatoid Arthritis | TNF | JNJ | 8/24/1998 | Antibody | | Debt | 30746 | Q123 |
| Simponi (golimumab) | Rheumatoid Arthritis | TNF | JNJ | 4/24/2009 | Antibody | | EV | 315898 | |
| Rotateq | Rotavirus | Vaccine | 100%? | 2006 | N/A | | | | |
| Gardasil | HPV | Vaccine | MEDI | 6/1/2006 | Injectable | | | | |
| Primaxin (cilastatin/imipenem) | Antibiotic | Antibiotic | 100%? | 11/26/1985 | | | CEO: Robert Davis | | |
| Lynparza (olaparib) | Oncology | PARP | AZN | 12/19/2014 | 2024 | | CMO: Eliav Barr | | |
| Lenvima (lenvatinib) | Oncology | TKI | 4523 JP | 2/13/2015 | 2025 | | | | |
| Lagevrio (molnupiravir) | COVID-19 | NRTI? | 1 | | | | | | |
| Bridion (sugammadex) | Anesthesia Reversal | | 1 | 12/15/2015 | 2026 | | | | |
| Reblozyl (luspatercept) | MDS | | BMY | 4/3/2020 | N/A | | | | |
| Padcev (enfortumab vedotin) | Urothelial Cancer | Nectin-4 ADC | SGEN, 4503 | | N/A | | | | |
| Belsomra (suvorexant, fka MK-4305 | Insomnia | Orexin | 1 | | | | | | |
| Welireg (belzutifan) | | | | 8/13/2021 | 2035 | | | | |
| Proquad | MMR+chicken pox | Vaccine | 1 | | N/A | | | | |
| Isentress (raltegravir) | HIV | Integrase | 1 | 10/1/2007 | | | | | |
| | | | | Phase | Admin | | | | |
| MK-0482 | Oncology | ILT3 mab | 1 | II | | | | | |
| MK-1942 | TRD | Unknown | | | | | | | |
| MK-4280 (favezelimab) | Oncology | LAG3 mab | 1 | II | | | | | |
| MK-2870/SKB264 | Oncology | TROP2 ADC | SKB | II | | | | | |
| MK-0616 | Hypercholesterolemia | PCSK9 oral | 1 | II | | | | | |
| MK-2060 | | FXI mab | 1 | II | | | | | |
| mRNA-4157/V940 | Melanoma | Vaccine | MRNA | II | | | | | |
| MK-5684/ODM-208 | | CYP11 inhibitor | ORNBV | II | | | | | |
| nemtabrutinib (fka MK-1026) | HemOnc | BTK inhibitor | 1 | II | | | | | |
| zilovertamab vedotin (MK-2140/VLS-101) | | ROR1 ADC | 100% (VelosBio) | II | | | | | |
| MK-4830 | Oncology | ILT4 mab | 1 | II | | | | | |
| quavonlimab (MK-1308) | Oncology | CTLA4 | 1 | II | | | | | |
| MK-5475 | PAH | sGC | 1 | II | | | | | |
| MK-3655 | NASH | FGFR | NGM | II | | | | | |
| MK-5890 | Oncology | CD27 | 1 | II | | | | | |
| MK-6024 (efinopegdutide) | NASH | GIP/GLP | Hanmi | II | | | | | |
| bomedemstat | Myelofibrosis | LSD1 inhibitor | 1 | II | | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| | | | 9/12/22: KEYNOTE-869 results | | | | | | |
| | | | 12/13/22: V940 results | | | | | | |
| | | | 12/15/22: Lynparza CRPC PDUFA extended | | | | | | |
| | | | 12/20/22: Padcev priority review for 1L UC | | | | | | |
| | | | 12/21/22: Lynparza approved in EU for CRPC | | | | | | |
| | | | 12/22/22: licenses 7 ADCs from Kelun-Biotech for $175m | | | | | | |
| | | | 12/22/22: investor conference | | | | | | |
| | | | 1/3/23: investor conference | | | | | | |
| | | | 1/5/23: Q4 earnings date | | | | | | |
| | | | 1/10/23: named JUST company | | | | | | |
| | | | 1/11/23: Completes Imago tender | | | | | | |